Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -78.30% is 26% above its 3-year average of -105.45%, near the high end of its 3-year range (-172.96%–-59.07%).
7.73% below its 12-month average of -72.68%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -25.37%.
RETURN ON ASSETS (ROA)
-78.30%
RETURN ON ASSETS (ROA) AVG TTM
-72.68%
RETURN ON ASSETS (ROA) AVG 3Y
-105.45%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.73%
CURRENT VS 3Y AVG
+25.75%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.55%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-232.41%
vs the sector median at left
Alumis Inc.
Market Cap
$844.28M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
N/A
Market Cap
$837.43M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$852.55M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$786.48M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$903.13M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$780.95M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$776.24M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | -78.30% | -72.68% | -105.45% | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -9.67% | -10.63% | -19.71% | -38.52% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -24.96% | -29.43% | -70.30% | -70.30% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -18.03% | -7.81% | -4.40% | -1.35% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -22.62% | -55.95% | -57.94% | -46.38% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -5.26% | 0.19% | -3.34% | -3.22% |
| Geron Corporation (GERN)vs › | $776.24M | -13.47% | -22.22% | -41.40% | -40.82% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -32.91% | -25.26% | -23.04% | -20.66% |
ROA
-78.3%
ROE
-97.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -59.07% |
| 2024-12-31 | -86.29% |
| 2023-12-31 | -172.96% |
| 2022-12-31 | -103.48% |
